DEFA14A

 

 

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

 

 

SCHEDULE 14A INFORMATION

Proxy Statement Pursuant to Section 14(a) of the

Securities Exchange Act of 1934

(Amendment No.    )

 

 

Filed by the Registrant                  Filed by a Party other than the Registrant  

Check the appropriate box:

 

Preliminary Proxy Statement

 

Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2))

 

Definitive Proxy Statement

 

Definitive Additional Materials

 

Soliciting Material Pursuant to § 240.14a-12

Horizon Therapeutics Public Limited Company

(Name of Registrant as Specified In Its Charter)

(Name of Person(s) Filing Proxy Statement if other than the Registrant)

Payment of Filing Fee (Check the appropriate box)

 

No fee required.

 

Fee computed on table below per Exchange Act Rules 14a-6(i)(1) and 0-11.

 

  1.

Title of each class of securities to which transaction applies:

 

 

 

  2.

Aggregate number of securities to which transaction applies:

 

 

 

  3.

Per unit price or other underlying value of transaction computed pursuant to Exchange Act Rule 0-11 (set forth the amount on which the filing fee is calculated and state how it was determined):

 

 

 

  4.

Proposed maximum aggregate value of transaction:

 

 

 

  5.

Total fee paid:

 

 

 

Fee paid previously with preliminary materials.

 

Check box if any part of the fee is offset as provided by Exchange Act Rule 0-11(a)(2) and identify the filing for which the offsetting fee was paid previously. Identify the previous filing by registration statement number, or the Form or Schedule and the date of its filing.

 

  1.

Amount Previously Paid:

 

 

 

  2.

Form, Schedule or Registration Statement No.:

 

 

 

  3.

Filing Party:

 

 

 

  4.

Date Filed:

 

 

 

 

 


LOGO

You invested in HORIZON THERAPEUTICS PLC and it’s time to vote!

You have the right to vote on proposals being presented at the Annual Meeting. This is an important notice regarding the availability of proxy material for the shareholder meeting to be held on April 29, 2021.

Get informed before you vote

View the Proxy Statement and the 2020 Annual Report to Shareholders online OR you can receive a free paper or email copy of the material(s) by requesting prior to April 15, 2021. If you would like to request a copy of the material(s) for this and/or future shareholder meetings, you may (1) visit www.ProxyVote.com, (2) call 1-800-579-1639 or (3) send an email to sendmaterial@proxyvote.com. If sending an email, please include your control number (indicated below) in the subject line. Unless requested, you will not otherwise receive a paper or email copy.

 

 

LOGO

 

*

Many shareholder meetings have attendance requirements including, but not limited to, the possession of an attendance ticket issued by the entity holding the meeting. Please check the meeting materials for any special requirements for meeting attendance. At the meeting, you will need to request a ballot to vote these shares.

V1


Vote at www.ProxyVote.com

 

 

THIS IS NOT A VOTABLE BALLOT

This is an overview of the proposals being presented at the

upcoming shareholder meeting. Please follow the instructions on

the reverse side to vote these important matters.

 

  Voting Items    Board
Recommends
 

  1.

 

  

Election of Class I Director Nominees:

 

  

  1a.

 

  

William F. Daniel

 

  

 

LOGO  For

 

 

  1b.

 

  

H. Thomas Watkins

 

  

 

LOGO  For

 

 

  1c.

 

  

Pascale Witz

 

  

 

LOGO  For

 

 

  2.

 

  

Approval of the appointment of PricewaterhouseCoopers LLP as our independent registered public accounting firm for our fiscal year ending December 31, 2021 and authorization of the Audit Committee to determine the auditors’ remuneration.

 

  

 

LOGO  For

 

 

  3.

 

  

Approval, on an advisory basis, of the compensation of our named executive officers, as disclosed in the Proxy Statement.

 

  

 

 

LOGO  For

 

 

  4.

 

  

Authorization for us and/or any of our subsidiaries to make market purchases or overseas market purchases of our ordinary shares.

 

  

 

 

LOGO  For

 

 

  5.

 

  

Approval of the Amended and Restated 2020 Equity Incentive Plan.

 

  

 

LOGO  For

 

  

    

 

  
          

 

Prefer to receive an email instead? While voting on www.ProxyVote.com, be sure to click “Sign up for E-delivery”.

 

 

D40223-P49855